Received Nov 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| ANTH | ANTHRAX (BIOTHRAX) | EMERGENT BIOSOLUTIONS | 3 | 300216A | IM / LA |
Approx 2 weeks after receipt of AVA dose #3, pt developed lesions on palms and soles (primarily small pink macules) and arthralgias. SSLR related to AVA has been considered in differential dx. Diagnostic work-up is ongoing, and includes Allergy/Immunology and ID consults. Sxms have been considered non-impairing and primary care team maintains this member on full-duty. Immunization Healthcare Division (submitting this VAERS) is also following and will consult on future vaccine recommendations.
None reported
None reported
None reported
None reported
Extensive diagnostic work-up is ongoing, and documented in EHR